CRMD250117P14000
- 0.00
- 0.000.00%
CorMedix Newsroom
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix (CRMD) Receives a Buy From Truist Financial
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Cormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth Prospects
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Sector Update: Health Care Stocks Mixed Premarket Tuesday
CorMedix Shares Advance After Reporting Preliminary Q4 Net Revenue
CorMedix | 8-K: CorMedix Inc. announces preliminary Fourth quarter 2024 results and provides business update
Express News | CorMedix Inc - Prelim, FY 2025 Operating Expense Guidance of $72-$78 Mln, Excluding Non-Cash & One-Time Items
Express News | CorMedix Inc - Has $25 Mln in Exisiting Open Purchase Orders for Q1 2025
CorMedix Sees 4Q Rev $31M >CRMD
Press Release: CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
Express News | CorMedix Q4 Cash & Investments USD 52 Million
CORMEDIX INC. ANNOUNCES PRELIMINARY FOURTH QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
CorMedix Price Target Raised to $12 From $11 at RBC Capital
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $12
CorMedix Added to Nasdaq Biotechnology Index